Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Research & Development: 2019-2024

Historic Research & Development for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $173.6 million.

  • Keros Therapeutics' Research & Development fell 60.35% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.4 million, marking a year-over-year decrease of 4.91%. This contributed to the annual value of $173.6 million for FY2024, which is 28.37% up from last year.
  • Per Keros Therapeutics' latest filing, its Research & Development stood at $173.6 million for FY2024, which was up 28.37% from $135.3 million recorded in FY2023.
  • Over the past 5 years, Keros Therapeutics' Research & Development peaked at $173.6 million during FY2024, and registered a low of $33.9 million during FY2020.
  • Moreover, its 3-year median value for Research & Development was $135.3 million (2023), whereas its average is $132.1 million.
  • Data for Keros Therapeutics' Research & Development shows a peak YoY spiked of 94.83% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Keros Therapeutics' Research & Development stood at $33.9 million in 2020, then soared by 62.86% to $55.1 million in 2021, then soared by 58.25% to $87.3 million in 2022, then spiked by 55.00% to $135.3 million in 2023, then increased by 28.37% to $173.6 million in 2024.